Drug intelligence / Profile preview

SIR-T CD19

Development stage: Preclinical
Lead developer: Angeles Therapeutics
Modality: Cell Therapies
Administration: Intravenous

Overview

SIR-T CD19 is an autologous cell therapy candidate developed by Angeles Therapeutics, utilizing their proprietary Synthetic Immune Receptor (SIR-T) platform. The therapy involves T cells engineered to express a synthetic receptor that specifically targets the CD19 antigen, a protein highly expressed on the surface of B-cell malignancies. The SIR-T platform is designed to integrate with the natural T-cell receptor (TCR) signaling complex, aiming to provide more physiological activation and improved persistence compared to traditional chimeric antigen receptor (CAR) T-cell therapies. Currently in IND-enabling studies, SIR-T CD19 is being developed for the treatment of various B-cell cancers, including lymphomas and leukemias.

Other names: SIR-T CD19

Targets

CD19 (B lymphocyte antigen CD19)

Beyond the preview

Go deeper on SIR-T CD19.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SIR-T CD19.

Explore the full profile